Table 1.
Studies using myeloablative IV busulfan (12.8 mg/kg or 520 mg/m2) and fludarabine
PK indicates pharmacokinetic; ivBU, intravenous busulfan; HLAid sib, HLA identical sibling; MUD, matched unrelated donor; MMUD, mis-matched unrelated donor; AL, acute leukemia; F, fludarabine; CTX, conditioning regimen; mMTX, micro-methotrexate; and FM, fludarabine plus melphalan.
*NRM for FM was not presented.
